Lisinopril

BreastfeedingPediatric
  • TRADE NAMES: Acerbon; Alapril; Carace; Coric; Prinil; Prinivil (Merck); Prinzide (Merck); Tensopril; Vivatec; Zestoretic (AstraZeneca); Zestril (AstraZeneca)
  • INDICATIONS: Hypertension; as adjunctive therapy in the management of heart failure; short-term treatment following myocardial infarction in hemodynamically stable patients
  • CLASS: Angiotensin-converting enzyme (ACE) inhibitor
  • HALF-LIFE: 12 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alcohol, Aldesleukin, Allopurinol, Alpha blockers, Alprostadil, Amifostine, Amiloride, Angiotensin II receptor antagonists, Antacids, Antidiabetics, Antihypertensives, Antipsychotics, Anxiolytics and hypnotics, Aprotinin, Azathioprine, Baclofen, Beta blockers, Calcium channel blockers, Clonidine, Corticosteroids, Cyclosporine, Diazoxide, Diuretics, Eplerenone, Estrogens, Everolimus, General anesthetics, Gold & Gold Compounds, Heparins, Hydralazine, Hypotensives, Insulin, Levodopa, Liraglutide, Lithium, MAO inhibitors, Metformin, Methyldopa, Methylphenidate, Minoxidil, Moxisylyte, Moxonidine, Nitrates, Nitroprusside, NSAIDs, Pentoxifylline, Phosphodiesterase 5 inhibitors, Potassium salts, Prostacyclin analogues, Rituximab, Salicylates, Sirolimus, Spironolactone, Sulfonylureas, Temsirolimus, Tizanidine, Tolvaptan, Triamterene, Trimethoprim, Yohimbine

PREGNANCY CATEGORY: D
category C in first trimester; category D in second and third trimesters

Prinzide and Zestoretic are lisinopril and hydrochlorothiazide.

Hydrochlorothiazide is a sulfonamide and can be absorbed systemically. Sulfonamides can produce severe, possibly fatal, reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome.

Contra-indicated in patients with a history of angioedema related to previous treatment with an ACE inhibitor and in patients with hereditary or idiopathic angioedema.

FETAL TOXICITY

See full prescribing information for complete boxed warning.

Our database has 64 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
RENAL
HEMATOLOGIC
OTHER


Page last updated 10/17/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric